You are here

Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Jyuzen General Hospital
Niihama-shi, Ehime, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-64 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Initial dose:

- 20 to 64 years

- Patients with undergoing mandibular impacted third molar tooth extraction accompanied
by lateral bone removal and crown cutting

- Patients with pain that meets both of the following criteria

- Pain intensity (4-categorical): "moderate pain" or "severe pain"

- Pain intensity (VAS): 45.0 mm or more

Additional dose:

- Patients with pain that corresponds to "4. Agree" or "5. Strongly agree" as the answer
to the "question about the pain intensity" during the period from 5 hours to 12 hours
post-initial dose of the study drug

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with acute inflammatory findings in the oral cavity necessitating treatment

- Patients who are scheduled to receive general anesthesia and analgesics in the process
of the eligible tooth extraction

NCT01062113
Pfizer
Completed
Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Moderate-severe Pain
NCT02101554
All Genders
7+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now